The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Personalis
Stock and Other Ownership Interests - Personalis
Patents, Royalties, Other Intellectual Property - Patent pending for use of KRAS as biomarker in pancreatic cancer. I am named as an inventor, patent owned my Personalis per employee agreement, no recurring compensation for patent specifically.
Circulating KRAS variant-specific shedding and association with survival in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving chemoimmunotherapy.
 
Jacob Edward Till
Stock and Other Ownership Interests - Pfizer (I); Sorrento Therapeutics
 
Lee McDaniel
No Relationships to Disclose
 
Shannon M. Pfeiffer
Employment - Genentech/Roche; Genentech/Roche (I)
Stock and Other Ownership Interests - Genentech/Roche (I)
Research Funding - Genentech/Roche (I)
Patents, Royalties, Other Intellectual Property - "Prediction and Characterization of DLBCL COO subtypes" (I)
 
Deena M. Maurer
No Relationships to Disclose
 
Jia Yu
No Relationships to Disclose
 
Christine Spencer
Patents, Royalties, Other Intellectual Property - CNS is a contributor on a US patent application (PCT/US17/53.717) submitted by the University of Texas MD Anderson Cancer Center that covers methods to enhance immune checkpoint blockade responses by modulating the microbiome.
 
Jaclyn P. Lyman
No Relationships to Disclose
 
Christopher R. Cabanski
No Relationships to Disclose
 
Diane M. Da Silva
No Relationships to Disclose
 
Charles Abbott
Employment - Personalis
Stock and Other Ownership Interests - Personalis
 
Sean Michael Boyle
Employment - Personalis
Stock and Other Ownership Interests - Personalis
Patents, Royalties, Other Intellectual Property - I have patents though my position and work at Personalis, Inc.
 
Osama E. Rahma
Employment - AstraZeneca; Outcomes4Me
Leadership - AstraZeneca; Outcomes4Me
Honoraria - Alaunus Global; Clinical Care Options/NCCN; Leerink; Merck; MI Bioresearch; PRMA Consulting
Consulting or Advisory Role - Alcimed; Bayer; Celgene; Defined Health; Five Prime Therapeutics; Genentech; GfK; GlaxoSmithKline; Imvax; Leerink; Maverick Therapeutics; Merck; PureTech; Putnam Associates; SOBI
Research Funding - Amgen; Merck
Patents, Royalties, Other Intellectual Property - PD-1/PD-L1 (Inst); Pending patent (DFCI 2386.010) (Inst)
Travel, Accommodations, Expenses - Clinical Care Options/NCCN; Genentech; Merck; PRMA Consulting; PureTech
 
George A. Fisher
Stock and Other Ownership Interests - Seagen (I)
Honoraria - Advanced Accelerator Applications; Ipsen
Consulting or Advisory Role - Ipsen; Merck; Taiho Pharmaceutical
Research Funding - Aduro Biotech (Inst); Forty seven (Inst); Genentech/Roche (Inst); Merck (Inst); Newlink Genetics (Inst)
Travel, Accommodations, Expenses - Merck; Roche/Genentech
Other Relationship - AstraZeneca; CytomX Therapeutics; Hutchison MediPharma; Silenseed; Taiho Pharmaceutical; Terumo Clinical Supply
 
Andrew H. Ko
Honoraria - BioAscent; Clinical Care Options; Medscape; PER; PlatformQ Health; Research to Practice
Consulting or Advisory Role - ERYTECH Pharma; Five Prime Therapeutics; Gritstone Bio; Imugene; Ipsen; Roche/Genentech; Signatera; SynCoreBio; Syros Pharmaceuticals; Turning Point Therapeutics; Tyme
Speakers' Bureau - Clinical Care Options
Research Funding - AbGenomics International (Inst); Apexigen (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); Leap Therapeutics (Inst); Merck (Inst)
 
Zev A. Wainberg
Consulting or Advisory Role - Amgen; Arcus Biosciences; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Five Prime Therapeutics; Ipsen; Lilly; Macrogenics; Merck; Merck KGaA; Novartis; Pfizer; PureTech; QED Therapeutics
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Bayer; Lilly; Merck
 
Robert A. Wolff
Honoraria - Modern Medicine
Patents, Royalties, Other Intellectual Property - Royalties from McGraw-Hill: Editor: M.D. Anderson Manual of Medical Oncology, 3rd edition.
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Adicet Bio (I); Alnylam (I); AstraZeneca (I); Autem Medical (I); BeiGene (I); Berry Genomics (I); BioSapien; BioSapien; Boehringer Ingelheim; Cend Therapeutics; CytomX Therapeutics; CytomX Therapeutics; Eisai (I); Exelixis (I); Flatiron Health (I); Genentech/Roche (I); Genoscience Pharma (I); Helio Health (I); IDEAYA Biosciences; Incyte (I); Ipsen (I); Legend Biotech (I); Merck; Nerviano Medical Sciences (I); Novartis; Noxxon Pharma; QED Therapeutics (I); Rafael Pharmaceuticals; RedHill Biopharma (I); Seagen; Thetis Pharma; Yiviva (I)
Research Funding - Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Celgene (Inst); Elicio Therapeutics (Inst); Genentech (Inst); Parker Institute for Cancer Immunotherapy (Inst); Roche (Inst); Silenseed (Inst)
 
Mark H. O'Hara
Consulting or Advisory Role - Geneos; Natera
Research Funding - Arcus Biosciences; Bristol-Myers Squibb; Celldex; Lilly; Natera; Parker Institute for Cancer Immunotherapy
Travel, Accommodations, Expenses - AstraZeneca/MedImmune
 
Robert H. Vonderheide
Patents, Royalties, Other Intellectual Property - Inventor on a licensed patient regarding cancer vaccine antigens; Receives royalties from Children’s Hospital Boston for a licensed research-only monoclonal antibody
 
Erica L. Carpenter
Honoraria - AstraZeneca
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Becton Dickinson (Inst); Janssen (Inst); Merck (Inst); Merck (Inst); United Health Group
Patents, Royalties, Other Intellectual Property - Invention disclosure entitled, "Methods and Compositions for Identifying, Diagnosing and Treating Neuroblastoma"; Invention disclosure entitled, "Methods and Compositions for Identifying, Diagnosing and Treating Neuroblastoma"; Invention disclosure entitled, "Methods and Compositions for Treating Neuroblastoma"
Travel, Accommodations, Expenses - AstraZeneca; Foundation Medicine